Clinical trial · Observational
Colorectal Cancer Dataset in Xijing Hospital From 2011
NCT06308354CI-TRIAL-00074986recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy | — | UNRESOLVED | — |
| Nutrition Related Cancer | — | UNRESOLVED | — |
| Prognostic Cancer Model | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- colorectal cancer
- description
- Colorectal cancer patients are enrolled when patients were underwent surgeries.
Primary outcomes (2)
- measure
- overall survival
- timeFrame
- from date of diagnosis until the date of death from any cause, assessed up to 120 months
- description
- to dead or lost to follow
- measure
- DFS
- timeFrame
- from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
- description
- disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome; * 2\. Visit our center with complete medical records and pathological information; * 3\. Colorectal cancer patients diagnosed between 2013 and 2023. Exclusion Criteria: * 1\. The patient has other colorectal malignancies other than adenocarcinoma; * 2\. Malignant tumors adjacent to organs invading the colon and rectum; * 3\. Malignant tumors from distant organs metastasize to the colon and rectum; * 4\. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
References
Publications (1)
- DERIVEDCao S, Qiao Y, Wu L, Chen Q, Tian K, Li J, Xing C. Postoperative adjuvant chemotherapy in patients with stage II early onset colorectal cancer: exploration and discovery using real-world data and the SEER database. Front Oncol. 2025 May 30;15:1566569. doi: 10.3389/fonc.2025.1566569. eCollection 2025. PMID 40519292